Skip to main content

Table 2 Responses based on IMWG criteria

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Variable

Pomalidomide plus dexamethasone (N = 36)

Response rate, n (%)

 Overall response

15 (41.7)

  Complete response

1 (2.8)

  Very good partial response

0

  Partial response

14 (38.9)

 Stable disease

16 (44.4)

 Progressive disease

5 (13.9)

 Not evaluable

0

Time to response, median (range), months

1.9 (0.9–5.5)

Duration of response, median (range), months

Not reached (1.9–11.1)

  1. IMWG International Myeloma Working Group